Effect of duration of MALG therapy in a quadruple immunosuppressive protocol.
Stratta
R J
RJ
Department of Surgery, University of Wisconsin School of Medicine, Madison.
D'Alessandro
A M
AM
Armbrust
M J
MJ
Pirsch
J D
JD
Sollinger
H W
HW
Kalayoglu
M
M
Belzer
F O
FO
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000627:therapeutic use*; D003929:Diabetic Neuropathies / Q000601:surgery; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D011897:Random Allocation; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D003524:Cyclosporins; D001379:Azathioprine; D011241:Prednisone; D008775:Methylprednisolone